Timothy Ray Brown was the first person publicly reported to be cured of HIV, an achievement that became known as the Berlin patient breakthrough. In 2007, he received a stem cell transplant to treat acute myeloid leukemia from a donor with a rare genetic mutation that conferred strong resistance to HIV. After intensive chemotherapy, radiation, and two transplants, reconstituting his immune system from donor cells suppressed HIV without ongoing antiretroviral therapy. Brown lived HIV-free for more than a decade after stopping treatment, demonstrating that a cure was possible and energizing research into safer, scalable approaches. This profile clarifies what happened, why it was scientifically pivotal, and how it shaped today’s cure agenda.
Key facts at a glance
Timothy Ray Brown’s case is documented through clinical reports, conference presentations, and follow-up studies that tracked his HIV status after stopping therapy. The following table summarizes verified, high-information details commonly referenced in scientific and patient-focused discussions.
| Attribute | Verified detail | Source type |
|---|---|---|
| Common name | Berlin patient | Reported clinical identifier |
| HIV status after transplant | Sustained remission without antiretroviral therapy | Published case reports and follow-up studies |
| Transplant year | 2007 | Medical conference announcements and journals |
| Condition treated | Acute myeloid leukemia | Clinical records |
| Donor cell feature | CCR5 Δ34/Δ34 mutation | Laboratory genetic analysis |
| Years of documented remission | Over 10 years after transplant before reported death | Long-term follow-up publications |
| Date of death | 2020 | Obituary and retrospective reports |
What happened: a step-by-step overview
Brown was diagnosed with HIV in 1995 and controlled the virus with antiretroviral therapy. In 2006, he was diagnosed with acute myeloid leukemia. His medical team pursued an allogeneic hematopoietic stem cell transplant to cure the cancer, selecting a donor whose cells carried two copies of the CCR5 Δ32 mutation, known to block HIV entry. Between 2007 and 2008, he underwent myeloablative conditioning (chemotherapy and total-body irradiation), a first transplant, a relapse, a second transplant, and prolonged immunosuppression. After engraftment, his new immune system consisted largely of CCR5-resistant cells. By design and observation, his viral load remained undetectable without antiretroviral drugs, leading clinicians to declare a functional cure, later referenced as remission.
Medical and scientific significance
The Berlin patient demonstration provided the first proof that a cure could be achieved in a human, validating the concept of HIV eradication through replacement of the immune system. It underscored the importance of viral reservoirs, the role of CCR5 as an HIV co-receptor, and the potential of stem cell approaches. Although the regimen was too toxic for routine use, it energized less aggressive strategies, including gene editing (e.g., CCR5 modification in autologous cells), elite controller research, and structured remission trials. Brown’s case remains a cornerstone reference in cure research because it showed durable control without therapy, influencing trial designs, regulatory considerations, and public expectations.
Important details to remember
- Brown’s remission required myeloablative conditioning and two stem cell transplants, carrying high short-term mortality and long-term toxicity risks.
- The donor’s CCR5 Δ32/Δ32 genotype was critical to the outcome, but most people living with HIV cannot use a matched CCR5-resistant donor safely.
- No antiretroviral therapy was used after the transplant; the absence of virus was attributed to replacement of the immune system with CCR5-resistant cells.
- In 2020, Brown died from recurrent cancer, not HIV-related causes, highlighting that the original cancer remained in remission while HIV control was maintained.
Relationship to other ‘Patient Zero’ and donor-derived cases
Brown is commonly called the Berlin patient, distinguishing him from other individuals treated for blood cancers who also experienced HIV remission after transplants from CCR5-resistant donors. Those cases, including the London patient and others reported later, reinforce that CCR5 blockade can enable sustained control, but they do not imply a scalable cure strategy for the millions living with HIV. Brown’s experience is best understood as a landmark scientific proof of concept, not a routine treatment pathway. It clarified what was biologically possible and shaped subsequent research focused on gene editing, latency-reversing agents, and immune-based therapies that might safely achieve remission without lethal transplants.
How this shapes today’s cure research and advocacy
Timothy Ray Brown’s legacy is a research roadmap and an ethical benchmark. His case established that durable HIV remission is achievable and justified investing in high-risk, high-reward science. Modern cure trials emphasize safety, use of autologous gene editing or donor cells with manipulated CCR5, and careful monitoring for residual virus and immune reconstitution issues. For people living with HIV today, the realistic near-term goals remain lifelong treatment with effective antiretroviral therapy, which preserves health and prevents transmission, while research pursues safer, scalable strategies inspired by the Berlin and related patient experiences. Brown’s story remains a pivotal reference point in ongoing efforts to end HIV as a life-long infection.